{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:52:33Z","timestamp":1768459953676,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NCATS Clinical and Translational Science","award":["TR000064"],"award-info":[{"award-number":["TR000064"]}]},{"name":"NIH\/NICHD","award":["HD043730"],"award-info":[{"award-number":["HD043730"]}]},{"DOI":"10.13039\/100001388","name":"Wenner-Gren Foundations in Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIAID","award":["R01 AI058150"],"award-info":[{"award-number":["R01 AI058150"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clim.2015.03.022","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:10:05Z","timestamp":1428279005000},"page":"140-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease"],"prefix":"10.1016","volume":"158","author":[{"given":"Phillip A.","family":"Doerfler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushrusha","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2015.03.022_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2015.03.022_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2015.03.022_bb0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.clim.2015.03.022_bb0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2015.03.022_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0035","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2015.03.022_bb0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0045","doi-asserted-by":"crossref","first-page":"e98336","DOI":"10.1371\/journal.pone.0098336","article-title":"Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent","volume":"9","author":"Nayak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2015.03.022_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2015.03.022_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2015.03.022_bb0070","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clim.2015.03.022_bb0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-012-0264-4","article-title":"Belimumab and the clinical data","volume":"14","author":"Shum","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.clim.2015.03.022_bb0080","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2015.03.022_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/TP.0b013e318246621d","article-title":"Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS\/BAFF","volume":"93","author":"Parsons","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2015.03.022_bb0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ajt.12984","article-title":"B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells","volume":"15","author":"Gorbacheva","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2015.03.022_bb0095","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/eji.201344186","article-title":"BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice","volume":"44","author":"Mari\u00f1o","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2015.03.022_bb0100","doi-asserted-by":"crossref","first-page":"e60430","DOI":"10.1371\/journal.pone.0060430","article-title":"BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(\u2212\/\u2212) mice","volume":"8","author":"Kyaw","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2015.03.022_bb0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.clim.2015.03.022_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.smim.2006.04.005","article-title":"The role of the BAFF\/APRIL system on T cell function","volume":"18","author":"Mackay","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.clim.2015.03.022_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1471-4906(03)00119-4","article-title":"Transitional B cells: step by step towards immune competence","volume":"24","author":"Chung","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2015.03.022_bb0120","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1073\/pnas.0807841105","article-title":"BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact","volume":"105","author":"Scholz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2015.03.022_bb0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T22:20:57Z","timestamp":1537741257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661615001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1521661615001254"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2015.03.022","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2015.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}